COVID-19 Hyperinflammatory Syndrome

How it works

Benefits

Risks & contraindications

Highlighted claims

• Severe COVID-19 pneumonia is characterised by respiratory and multiorgan failure in the context of marked systemic inflammation and elevated thrombotic risk. — Multiarm multistage randomised controlled trial of inflammatory signal inhibitors (MATIS) for patients hospitalised with COVID-19 pneumonia during the UK pandemic
• Elevated circulating inflammatory molecules are associated with poor prognosis and in a subset of patients drive acute lung injury leading to organ failure and death. — Multiarm multistage randomised controlled trial of inflammatory signal inhibitors (MATIS) for patients hospitalised with COVID-19 pneumonia during the UK pandemic
• Tocilizumab (an IL-6 inhibitor) was found to reduce mortality by 15% versus usual care in the RECOVERY trial. — Multiarm multistage randomised controlled trial of inflammatory signal inhibitors (MATIS) for patients hospitalised with COVID-19 pneumonia during the UK pandemic
• The balance between permitting adequate antiviral immune responses and preventing hyperinflammatory escalation represents a narrow, poorly defined therapeutic window. — Multiarm multistage randomised controlled trial of inflammatory signal inhibitors (MATIS) for patients hospitalised with COVID-19 pneumonia during the UK pandemic
• The MATIS investigators hypothesised a narrow early therapeutic window in which inflammatory signal inhibitors could interrupt COVID-19 hyperinflammatory syndrome before acute lung injury progresses irreversibly. — Multiarm multistage randomised controlled trial of inflammatory signal inhibitors (MATIS) for patients hospitalised with COVID-19 pneumonia during the UK pandemic